causalyAI

Heading to ACE Drug Discovery Summit in London? Don't miss our talk on how human-centric GenAI can unlock biomedical knowledge. 📅 Mark your calendar: March 20 at 10 AM. #ACEDrugDiscovery #AI #BioTech

We're headed to the ACE Drug Discovery Summit from March 20-21, and we can't wait to connect with you all! #ACEDrugDiscovery #DrugDiscovery #AIinHealthcare

R&D leaders are facing challenges in deploying AI at scale. Join our upcoming webinar as we explore how the right technology, processes, and partnerships can help effectively scale AI initiatives. See the agenda 👉 hubs.la/Q02pflbH0 #GenAI #LifeSciences #Biotech #LLMs

Drug discovery scientists are leveraging AI to unravel complex disease mechanisms, enabling the identification of novel biomarkers and therapeutic targets with unprecedented precision. Read our latest blog for more insights: hubs.la/Q02nlyX20 #AI #Mechanisms #Discovery

A staggering 75% of preclinical safety failures are attributed to compounds being off-target. Download our latest report to understand how #AI can be a strategic advantage for deciphering secondary #MoAs and potential off-target effects. hubs.la/Q02n8KQG0

Causaly’s AI can sift through and remove irrelevant data from biomedical searches, offering a more comprehensive view of of entire research landscapes. Read our blog for more insights: hubs.la/Q02mKkrq0 #Innovation #AI #Research

IT'S TOMORROW! Don't miss our virtual panel discussion celebrating Women in Science: Breaking Barriers, Driving Change, and Navigating Success Let's inspire change together! Register Now: hubs.la/Q02mvZpZ0 #WomenInScience #Empowerment #FutureLeaders

A founder's perspective on our journey to Causaly's production-grade GenAI Copilot from our co-founder and CEO, Yiannis Kiachopoulos. Read more: hubs.la/Q02mnR9w0 #GenAI #Biotech

Empowering Women in Science: Breaking Barriers, Driving Change, and Navigating Success Join us as we celebrate Women in Science with our virtual discussion: hubs.la/Q02m1JZT0

See how AI can aid drug repurposing investigations by accelerating the identification of novel drug-disease connections, opening up new treatment avenues in unexplored indications. Get insights here: hubs.la/Q02m4YH20 #AI #Discovery

Join our CEO in the upcoming webinar as he delves into the challenges of scaling #AI initiatives in R&D and how leaders can set up their teams for success. hubs.la/Q02m1BJk0

Facing average out-of-pocket costs of $1.4 billion to bring a drug to market, pharma companies are compensating for negative R&D productivity through mergers and acquisitions. See how AI can help in our latest blog: hubs.la/Q02kQ_1-0 #DrugDiscovery #AI #Pharma

Unmanageable toxicity accounts for 30% of clinical drug development failures. Discover how AI-powered insights could help reduce safety-related drug attrition in out latest report: hubs.la/Q02kHgZ10 #DrugDiscovery #SafetySignals #AI

The discovery of safety biomarkers is key for mitigating toxicity risks, speeding up the delivery of safe drugs to patients. Explore how AI can enhance this process by efficiently identifying biomarkers from vast biomedical literature: hubs.la/Q02ktPnr0 #SafetyBiomarkers

"Causaly Cloud doubles or triples my [research] capacity." Discover the impact of Causaly Cloud and the benefits it offers to pharma organizations. Request our recent Forrester Total Economic Impact Study of Causaly Cloud now: hubs.la/Q02ktWl00 #Biotech

🔬Targeting drugs at the main pathophysiological process can play a key role in drug discovery success. Yet, identifying relevant targets and pathways is challenging. See how Causaly's AI can help decipher complex disease biology: hubs.la/Q02k01r60 #DrugDiscovery #AI

A comprehensive understanding of relevant pathways and targets early on in development is key to anticipating potential side effects. By rapidly processing large volumes of data into actionable insights, AI can help forecast potential toxicity concerns: hubs.la/Q02j6ttc0

The strategic prioritization of targets by class offers a competitive edge in drug discovery. Causaly's AI enables researchers to identify and prioritize targets by class, providing a more granular view of targets for a disease: hubs.la/Q02hSgZX0 #TargetClass #AI

Did you know 30% of clinical drug development failures are due to unmanageable toxicity? Download our latest report to discover how AI-powered insights could help reduce safety-related drug attrition: hubs.la/Q02hJgrH0 #FDA #Toxicity #AIDrugDiscovery

Traditional keyword searching is inefficient and subject to bias, leading to missed opportunities. With human-centric AI, scientists can remove bias from the process, extracting meaningful, in-depth insights in a fraction of the time. hubs.la/Q02hxNJR0 #RemoveBias #AI